<DOC>
	<DOC>NCT02003144</DOC>
	<brief_summary>The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.</brief_summary>
	<brief_title>An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients</brief_title>
	<detailed_description>This study is an open label extension study to confirm the long term safety and efficacy of eculizumab in subjects with relapsing NMO who have completed the initial double-blind, randomized, placebo-controlled trial ECU-NMO-301.</detailed_description>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>Key 1. Patient completed the ECUNMO301 trial 2. Patient has given written informed consent Key 1. Patients who have withdrawn from the ECUNMO301 trial as a result of an AE related to trial drug 2. Female patients who are pregnant, breastfeeding, or intend to conceive during the course of the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Long-term safety study</keyword>
	<keyword>Extension trial</keyword>
	<keyword>Eculizumab</keyword>
	<keyword>Neuromyelitis Optica Spectrum Disorder</keyword>
	<keyword>Devic's disease</keyword>
	<keyword>Transverse Myelitis</keyword>
	<keyword>Optic Neuritis</keyword>
	<keyword>Relapse</keyword>
	<keyword>NMO-IgG</keyword>
	<keyword>CNS Autoimmune Disorders</keyword>
	<keyword>Demyelinating Disorders</keyword>
</DOC>